Maxim Group reaffirmed their hold rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a report released on Monday, May 15th, StockTargetPrices.com reports.
A number of other analysts have also issued reports on BLUE. BMO Capital Markets reiterated a market perform rating and set a $83.00 price objective on shares of bluebird bio in a research note on Thursday, February 23rd. Morgan Stanley boosted their price objective on bluebird bio from $58.00 to $87.00 and gave the company an equal weight rating in a research note on Wednesday, March 1st. Roth Capital restated a neutral rating and issued a $71.00 target price (down from $87.00) on shares of bluebird bio in a research note on Monday, February 6th. Zacks Investment Research lowered bluebird bio from a buy rating to a hold rating in a research note on Thursday, February 9th. Finally, Jefferies Group LLC restated a buy rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday, March 24th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. bluebird bio presently has a consensus rating of Buy and a consensus target price of $94.61.
bluebird bio (NASDAQ:BLUE) traded down 1.49% on Monday, reaching $108.75. The company’s stock had a trading volume of 1,555,990 shares. bluebird bio has a 12 month low of $36.62 and a 12 month high of $116.90. The firm’s market cap is $4.45 billion. The firm has a 50 day moving average of $91.57 and a 200 day moving average of $81.07.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.76) by $0.08. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. The company had revenue of $6.83 million for the quarter, compared to analyst estimates of $1.51 million. Analysts anticipate that bluebird bio will post ($6.74) earnings per share for the current year.
In other news, Director Daniel Lynch sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $80.00, for a total value of $160,000.00. Following the completion of the transaction, the director now owns 3,400 shares of the company’s stock, valued at approximately $272,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Davidson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $90.89, for a total value of $272,670.00. Following the transaction, the insider now directly owns 20,177 shares of the company’s stock, valued at approximately $1,833,887.53. The disclosure for this sale can be found here. Insiders sold a total of 34,258 shares of company stock valued at $3,263,236 in the last three months. Corporate insiders own 3.90% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock worth $289,259,000 after buying an additional 3,175,124 shares during the period. FMR LLC raised its position in bluebird bio by 9.2% in the fourth quarter. FMR LLC now owns 6,088,971 shares of the biotechnology company’s stock worth $375,689,000 after buying an additional 513,477 shares during the period. Norges Bank bought a new position in bluebird bio during the fourth quarter worth $22,940,000. Alyeska Investment Group L.P. bought a new position in bluebird bio during the fourth quarter worth $18,270,000. Finally, Baker BROS. Advisors LP bought a new position in bluebird bio during the third quarter worth $19,923,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.